0001600132 false 0001600132 2023-10-12 2023-10-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 12, 2023

 

Bellerophon Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-36845   47-3116175
(State or Other Jurisdiction of Incorporation)     (Commission
File Number)		   (IRS Employer
Identification No.)

 

20 Independence Boulevard, Suite 402
Warren, New Jersey		   07059
(Address of Principal Executive Offices)     (Zip Code)

 

Registrant’s telephone number, including area code: (908) 574-4770

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class     Trading
Symbol(s)		   Name of each exchange on which
registered
Common Stock, $0.01 par value per share     BLPH   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

¨ Emerging growth company

 

¨If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On October 12, 2023, Theodore Wang notified the board of directors (the “Board”) of Bellerophon Therapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board, effective immediately. The resignation of Mr. Wang from the Company’s board of directors was due to a disagreement as to whether the Company’s board of directors should approve the plan of liquidation and dissolution of the Company.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BELLEROPHON THERAPEUTICS, INC.
     
Date: October 13, 2023 By: /s/ Peter Fernandes
    Name: Peter Fernandes
    Title: Chief Executive Officer

 

 

 

v3.23.3
Cover
Oct. 12, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 12, 2023
Entity File Number 001-36845
Entity Registrant Name Bellerophon Therapeutics, Inc.
Entity Central Index Key 0001600132
Entity Tax Identification Number 47-3116175
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 20 Independence Boulevard
Entity Address, Address Line Two Suite 402
Entity Address, City or Town Warren
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07059
City Area Code 908
Local Phone Number 574-4770
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol BLPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Bellerophon Therapeutics (NASDAQ:BLPH)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Bellerophon Therapeutics Charts.
Bellerophon Therapeutics (NASDAQ:BLPH)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Bellerophon Therapeutics Charts.